TY - JOUR
T1 - Subversion of NK-cell and TNFα immune surveillance drives tumor recurrence
AU - Kottke, Tim
AU - Evgin, Laura
AU - Shim, Kevin G.
AU - Rommelfanger, Diana
AU - Boisgerault, Nicolas
AU - Zaidi, Shane
AU - Diaz, Rosa Maria
AU - Thompson, Jill
AU - Ilett, Elizabeth
AU - Coffey, Matt
AU - Selby, Peter
AU - Pandha, Hardev
AU - Harrington, Kevin
AU - Melcher, Alan
AU - Vile, Richard
N1 - Funding Information:
This work was supported by The European Research Council, The Richard M. Schulze Family Foundation, the Mayo Foundation, Cancer Research UK, the NIH (R01 CA175386 and R01 CA108961), the University
Publisher Copyright:
©2017 AACR.
PY - 2017/11
Y1 - 2017/11
N2 - Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)–mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse.
AB - Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition is mediated through the subversion of two key elements of innate immunosurveillance. In the first, the role of TNFα changes from an antitumor effector against primary tumors into a growth promoter for MRD. Second, whereas primary tumors induced a natural killer (NK)–mediated cytokine response characterized by low IL6 and elevated IFNγ, PD-L1hi MRD cells promoted the secretion of IL6 but minimal IFNγ, inhibiting both NK-cell and T-cell surveillance. Tumor recurrence was promoted by trauma- or infection-like stimuli inducing VEGF and TNFα, which stimulated the growth of MRD tumors. Finally, therapies that blocked PD-1, TNFα, or NK cells delayed or prevented recurrence. These data show how innate immunosurveillance mechanisms, which control infection and growth of primary tumors, are exploited by recurrent, competent tumors and identify therapeutic targets in patients with MRD known to be at high risk of relapse.
UR - http://www.scopus.com/inward/record.url?scp=85033380381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033380381&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-17-0175
DO - 10.1158/2326-6066.CIR-17-0175
M3 - Article
C2 - 29038298
AN - SCOPUS:85033380381
SN - 2326-6066
VL - 5
SP - 1029
EP - 1045
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 11
ER -